The year in gout: 2010-2011

Bulletin of the NYU Hospital for Joint Diseases

Volumn 69, Issue 3, 2011, Pages 257-263

  Crittenden, Daria B ^a,b   Pillinger, Michael H ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE; CANAKINUMAB; COLCHICINE; FEBUXOSTAT; INTERLEUKIN 1BETA; PEGLOTICASE; PROBENECID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TRANILAST; TRIAMCINOLONE; URATE;

ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; DIET; DISEASE COURSE; GOUT; HUMAN; HYPERURICEMIA; INFLAMMATION; INNATE IMMUNITY; KIDNEY DISEASE; PATHOPHYSIOLOGY;

GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; TREATMENT OUTCOME;

EID: 80054109730     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford). 2009;48 Suppl 2:ii2-ii8.
2. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010;12(6):223.
3. Demarco MA, Maynard JW, Huizinga MM, et al. Obesity and younger age at gout onset in a community-based cohort. Arthritis Care Res (Hoboken). 2011;63(8):1108-14.
4. Choi JW, Ford ES, Gao X, Choi HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008;59:109-16.
5. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336(7639):309-12.
6. Yu KH, See LC, Huang YC, Yang CH, Sun JH. Dietary factors associated with hyperuricemia in adults. Semin Arthritis Rheum. 2008;37(4):243-50.
7. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol. 2011;23(2):192-202.
8. Centers for Disease Control and Prevention. Public health and aging: trends in aging-United States and worldwide. Morbidity and Mortality Weekly Report. 2003;52:101-6.
9. Zhu Y, Pandya B, Choi H. Increasing gout prevalence in the US over the last two decades: the National Health and Nutrition Examination Survey (NHANES). Arthritis Rheum. 2010;62:S910(2154).
10. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyper-uricemia in the US general population. Arthritis Rheum. 2011 [Epub ahead of print].
11. Wu EQ, Forsythe A, Guerin A, et al. Comorbidity Burden, Healthcare Resource Utilization, and Costs in Chronic Gout Patients Refractory to Conventional Urate-Lowering Therapy. Am J Ther. 2011 [Epub ahead of print].
12. Kaneko K, Taniguchi N, Tanabe Y, et al. Oxidative imbalance in idiopathic renal hypouricemia. Pediatr Nephrol. 2009;24(4):869-71.
13. So A, Thorens B. Uric acid transport and disease. J Clin Invest. 2010;120(6):1791-9.
14. Woodward OM, Kottgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009;106(25):10338-42.
15. Yang Q, Kottgen A, Dehghan A, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet. 2010;3(6):523-30.
16. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-41.
17. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229-65.
18. Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. 2005;52(9):2936-46.
19. Chen CJ, Shi Y, Hearn A, et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest. 2006;116(8):2262-71.
20. Ng G, Sharma K, Ward SM, et al. Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity. 2008;29(5):807-18.
21. Weissmann G, Rita GA. Molecular basis of gouty inflammation: interaction of monosodium urate crystals with lysosomes and liposomes. Nat New Biol. 1972;240(101):167-72.
22. Petrilli V, Papin S, Dostert C, et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 2007;14(9):1583-9.
23. Schorn C, Frey B, Lauber K, et al. Sodium overload and water influx activate the NALP3 inflammasome. J Biol Chem. 2011;286(1):35-41.
24. Bardin T, Varghese Cherian P, Schumacher HR. Immunoglobulins on the surface of monosodium urate crystals: an immunoelectron microscopic study. J Rheumatol. 1984;11(3):339-41.
25. Kam M, Perl-Treves D, Caspi D, Addadi L. Antibodies against crystals. FASEB J. 1992;6(8):2608-13.
26. Kanevets U, Sharma K, Dresser K, Shi Y. A role of IgM anti-bodies in monosodium urate crystal formation and associated adjuvanticity. J Immunol. 2009;182(4):1912-8.
27. Choi HK, Willett W, Curhan G. Fructose-rich beverages and risk of gout in women. JAMA. 2010;304(20):2270-8.
28. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;52(1):283-9.
29. Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350(11):1093-103.
30. Ghadirian P, Shatenstein B, Verdy M, Hamet P. The influence of dairy products on plasma uric acid in women. Eur J Epidemiol. 1995;11(3):275-81.
31. Dalbeth N, Wong S, Gamble GD, et al. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Ann Rheum Dis. 2010;69(9):1677-82.
32. Dalbeth N, Palmano K. Effects of dairy intake on hyperuricemia and gout. Curr Rheumatol Rep. 2011;13(2):132-7.
33. Dalbeth N, Gracey E, Pool B, et al. Identification of dairy fractions with anti-inflammatory properties in models of acute gout. Ann Rheum Dis. 2010;69(4):766-9.
34. Choi HK, Curhan G. Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. Arthritis Rheum. 2007;57(5):816-21.
35. Choi HK, Willett W, Curhan G. Coffee consumption and risk of incident gout in men: a prospective study. Arthritis Rheum. 2007;56(6):2049-55.
36. Neogi T, Chen C, Chaisson C, Hunter DJ, Zhang Y. Short-term effects of caffeinated beverage intake on risk of recurrent gout attacks. Arthritis Rheum. 2010;62:S565(1362).
37. Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124(2):155-63.
38. Shah A, Keenan RT. Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? Curr Rheumatol Rep. 2010;12(2):118-24.
39. Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM. Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol. 2011;71(4):600-7.
40. Chen J-H, Pan W-H. Effects of urate lowering therapy on cardiovascular mortality: a Taiwanese cohort study. Arthritis Rheum. 2010;62:S872-3(2088).
41. Whelton A, Macdonald PA, Zhao L, et al. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011;17(1):7-13.
42. Krishnamurthy A, Lazaro DM, Blumenthal DR, et al. The effect of allopurinol on renal function in patients with hyperuricemia: a case-control study. Arthritis Rheum. 2010;62:S68:161.
43. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388-93.
44. Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008;58(9):2882-91.
45. Sundy JS, Becker MA, et al. Efficacy and safety of intravenous pegloticase (PGL) in treatment failure gout: results from GOUT1 and GOUT2. Arthritis Rheum. 2008;58:S400-1.
46. Baraf HS, Matsumoto AK, Maroli AN, Waltrip RW 2nd. Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis Rheum. 2008;58(11):3632-4.
47. Baraf H, Gutierrez-Urena SR, Vazquez-Mellado J, et al. Progressive reduction in tophus burden wtih pegloticase therapy in patients with chronic gout refractory to conventional therapy. Arthritis Rheum. 2010;62:S66:157.
48. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.
49. Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis. 2009;68(10):1613-7.
50. Terkeltaub R, Schumacher HR, Curtis C, et al. Evaluation of rilonacept for prevention of gout flares during initiation of urate-lowering therapy: results of a phase 3, randomized, double blind, placebo-controlled trial. Arthritis Rheum. 2010;62:S64.
51. So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62(10):3064-76.
52. Schlesinger N, De Meulemeester M, et al. Efficacy of canakinumab (ACZ885), a fully human anti-interleukin(IL)-1beta monoclonal antibody, in the prevention of flares in gout patients initiating allopurinol therapy. Arthritis Rheum. 2010;62:S872.
53. Perez-Ruiz F, Hingorani V, Welp J, et al. Efficacy and safety of a range of doses of FDEA594, a novel uricosuric agent, as a single agen in hyperuricemic gout patients: multicenter, randomized, double-blind, placebo-controlled phase 2 experience. Ann Rheum Dis. 2010;69:121.
54. Perez-Ruiz F, Sundy JS, Krishnan E, et al. Efficacy and safety of lesinurad (RDEA594), a novel uricosuric agent, given in combination with allopurinol in allopurinol-refractory gout patients: randomized, double-blind, placebo-controlled, phase 2B study. Ann Rheum Dis. 2011;70:104.
55. Pharmacokinetics and serum urate lowering effect of RDEA594, a novel URAT1 inhibitor, in gout patients and subjects with varying degrees of renal impairment. 2011. Available from: www.ascpt.org/Meetings/PastAnnualMeetings/2011AnnualMeeting/SpeakerPresentations/tabid/8513/Default.aspx.
56. Sundy JS, Kitt MM, Griffith SG, et al. The combination of tranilast with allopurinol results in enhanced urate lowering. Arthritis Rheum. 2010;62:S67-8:160.
57. Fields TR, Abramson SB, Weissmann G, et al. Activation of the alternative pathway of complement by monosodium urate crystals. Clin Immunol Immunopathol. 1983;26(2):249-57.
58. Malawista SE, Duff GW, Atkins E, et al. Crystal-induced endogenous pyrogen production. A further look at gouty inflammation. Arthritis Rheum. 1985;28(9):1039-46.
59. Wilson JM, Young AB, Kelley WN. Hypoxanthine-guanine phosphoribosyltransferase deficiency. The molecular basis of the clinical syndromes. N Engl J Med. 1983;309(15):900-10.
60. Lesch M, Nyhan WL. A familial disorder of uric acid metabolism and central nervous system function. Am J Med. 1964;36:561-70.
61. Seegmiller JE. Genetic considerations of gout. Arthritis Rheum. 1975;18(6 Suppl):743-6.
62. Schumacher HR Jr. Pathology of crystal deposition diseases. Rheum Dis Clin North Am. 1988;14(2):269-88.